Pfizer and BioNTech to develop first mRNA-based Shingles vaccine
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The drug is priced at Rs 2000 for a course of 40 tablets
The transaction is expected to close in the first quarter of 2022
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
The Academy endeavours to reach all levels of the society in creating programs that are accessible to one and all with training for Health Volunteers, Asha, Angavadi, school-teachers and students as part of life-skill development
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Subscribe To Our Newsletter & Stay Updated